StockNews.AI
CSBR
StockNews.AI
42 days

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models

1. CSBR launches integrated radiopharmaceutical services platform. 2. Expanded license supports ten key isotopes for oncology studies. 3. CSBR aims to enhance drug development with advanced workflows. 4. Unique PDX tumor models differentiate CSBR in the market.

5m saved
Insight
Article

FAQ

Why Bullish?

The launch of a differentiated services platform positions CSBR favorably amidst growing demand for radiopharmaceuticals. Historically, innovative launches in biotech such as CAR-T therapies have led to significant stock price increases.

How important is it?

This announcement aligns with industry trends toward precision oncology, which may draw investor interest and elevate the company's prospects for future contracts.

Why Long Term?

The integration of new technologies into CSBR's offerings is likely to have sustained positive effects, as adoption in the biopharma industry builds over time and long-term contracts may materialize.

Related Companies

NDAQ:IONSNDAQ:EDITNDAQ:ABBVNDAQ:REGNNDAQ:EXAS
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems."Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world's most deeply characterized PDX bank, we're helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development."Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches."Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumor biology," continued Mike Ritchie, Chief Commercial Officer at Champions Oncology. "The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumor targeting, and therapeutic effect."To learn more about Champions Oncology's radiopharmaceutical capabilities, visit:https://www.championsoncology.com/radiopharmaceuticalAbout Champions OncologyChampions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.Media ContactGavin CooperVice President, Global Marketing[email protected]518 488 9026SOURCE: Champions Oncology, Inc.

Related News